According to SEC filings, Svetlana Dey, a director at Bluejay Diagnostics, Inc. (NASDAQ:BJDX), purchased $25,000 worth of common stock from the company on March 14, 2026. This transaction involved acquiring 12,500 shares at a unit price of $2.00 per share, executed through a private placement directly from the issuer.
Following this specific acquisition, Ms. Dey's direct holdings increased by one share, bringing her total count to 12,501 shares of Bluejay Diagnostics common stock. This purchase was notable given the current market valuation of BJDX. At the time of reporting, the stock was trading at $1.72, which is close to its 52-week low of $1.65. Furthermore, the stock had experienced a decline of 77% over the past year.
The company's financial standing, as reported by InvestingPro data, shows a market capitalization of only $1.73 million and carries a 'WEAK' financial health rating. Despite these metrics, Ms. Dey also maintains an indirect stake in the company through Lana Management & Business Research International, LLC. This entity is jointly owned by Ms. Dey and Mr. Indranil Dey. Crucially, Ms. Dey retains voting and dispositive power over the shares held within this LLC.
Recent corporate developments at Bluejay Diagnostics further contextualize these insider transactions. In a separate instance of capital raising, the company completed a private placement involving 62,500 shares of common stock, priced at $2.00 per share. This activity generated total gross proceeds amounting to $125,000. The purchasers for this larger tranche included five members of the board of directors, specifically naming President and CEO Neil Dey and Chair of the Board Donald Chase among them.
In addition to these private placements, Bluejay Diagnostics finalized the full exercise of all prefunded warrants originating from its October 2025 private placement. As of February 19, there are no remaining prefunded warrants outstanding following this comprehensive exercise. This action resulted in approximately 972,000 shares of common stock now being outstanding for the company.
Beyond capital structuring and insider trading, Bluejay Diagnostics has been engaged in ongoing corporate communications. The company issued a response letter on March 13th to NorthStrive Fund II LP. This response followed a correspondence that had been received from NorthStrive Fund II LP on March 11th. While the specific content of both letters remains undisclosed, a copy of Bluejay Diagnostics' response was included as an exhibit within a recent SEC filing. These cumulative activities reflect active corporate management and continued shareholder engagement.
Risks
- The stock's performance is characterized by significant volatility, trading near its 52-week low while having declined 77% over the past year.
- Financial health metrics are flagged as 'WEAK' by InvestingPro data, coupled with a very low market capitalization of $1.73 million.
- The reliance on private placements and warrant exercises suggests ongoing capital needs and potential dilution effects for existing shareholders.
More from Insider Trading
Risks
- The stock's performance is characterized by significant volatility, trading near its 52-week low while having declined 77% over the past year.
- Financial health metrics are flagged as 'WEAK' by InvestingPro data, coupled with a very low market capitalization of $1.73 million.
- The reliance on private placements and warrant exercises suggests ongoing capital needs and potential dilution effects for existing shareholders.